Go to main content
Tricals - The highway towards a cure
ALS Centre the Netherlands

UMC Utrecht

The Netherlands - Utrecht

ALS Centre Netherlands is the expertise centre in the field of ALS, PSMA and PLS. The ALS Centre is located in the UMC Utrecht.

Approximately 90% of all Dutch ALS patients (more than 500 per year) are diagnosed in our centre. We plan all diagnostic tests and consultations for a patient in one day. Prof. Dr. Leonard van den Berg, coordinator of the ALS Centre Netherlands, is one of the initiators of the TRICALS platform, with the aim of scaling up research into ALS treatment by improving cooperation between patients, industry and ALS centres. He is also one of the initiators of Project Mine, which is one of the largest research initiatives worldwide investigating the genetic basis of ALS. The research of the ALS Centre Netherlands focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.

Specialists in this centre

Leonard van den Berg

Professor of Neurology

Jan Veldink

Neurologist

Michael van Es

Neurologist

Tommy Bunte

Physician Assistant

Andrea van Zijl

Research nurse

Arianne de Fockert

Research assistant

Bianca Broere

Clinical research coordinator

Hanneke Jansen

Research nurse

Karen Vlaardingerbroek

Research nurse

Mirjam van Noord

Research nurse

Location

Heidelberglaan 100, 3584 CX,Utrecht,The Netherlands

Contact

Current trials in this centre

Open for participation

PRO-101 trial

Phase 1
Industry
No

In this research we investigate the safety of the new drug prosetin for the treatment of ALS.

More about this trial

Open for participation

MAGNET lithium trial

Phase 3
IIT
UNC13A

The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.

More about this trial

Open for participation

reALiSe

Phase 2
Industry
No

In the reALiSe study the safety and efficacy of the drug ARGX-119 for the treatment of ALS is investigated.

More about this trial

Closed for participation

DAZALS

Phase 2
Industry
No

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

More about this trial

Closed for participation

VRG50635 trial

Phase 1
Industry
No

Verge Genomics is conducting a phase 1b trial to evaluate the safety, tolerability, and potential efficacy of VRG50635.

More about this trial

Closed for participation

FUSION

Phase 3
Industry
FUS

This study investigates the safety & efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene.

More about this trial

Closed for participation

Lighthouse 2

Phase 3
IIT
No

The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.

More about this trial

Archived

TUDCA-ALS

Phase 3
IIT
No

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

CardinALS

Phase 2
Industry
No

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

RT001 trial

Phase 2
Industry
No

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS.

More about this trial

Archived

APL2-ALS-206 trial

Phase 2
Industry
No

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

More about this trial

Archived

COURAGE-ALS

Phase 3
Industry
No

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

More about this trial

Archived

ALXN1210-ALS-308 trial

Phase 3
Industry
No

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.